Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Chiara Cattaneo; Jon Salmanton-García; Francesco Marchesi; Shaimaa El-Ashwah; Federico Itri; Barbora Weinbergerová; Maria Gomes Da Silva; Michelina Dargenio; Julio Dávila-Valls; Sonia Martín-Pérez; Francesca Farina; Jaap Van Doesum; Toni Valković; Caroline Besson; Christian Bjørn Poulsen; Alberto López-García; Pavel Žák; Martin Schönlein; Klára Piukovics; Ozren Jaksic; Alba Cabirta; Natasha Ali; Uluhan Sili; Nicola Fracchiolla; Giulia Dragonetti; Tatjana Adžić-Vukičević; Monia Marchetti; Marina Machado; Andreas Glenthøj; Olimpia Finizio; Fatih Demirkan; Ola Blennow; Maria Chiara Tisi; Ali S Omrani; Milan Navrátil; Zdeněk Ráčil; Jan Novák; Gabriele Magliano; Moraima Jiménez; Carolina Garcia-Vidal; Nurettin Erben; Maria Ilaria Del Principe; Caterina Buquicchio; Rui Bergantim; Josip Batinić; Murtadha Al-Khabori; Luisa Verga; Tomáš Szotkowski; Michail Samarkos; Irati Ormazabal-Vélez; Stef Meers; Johan Maertens; László Imre Pinczés; Martin Hoenigl; Ľuboš Drgoňa; Annarosa Cuccaro; Yavuz M Bilgin; Avinash Aujayeb; Laman Rahimli; Stefanie Gräfe; Mariarita Sciumè; Miloš Mladenović; Gökçe Melis Çolak; Maria Vittoria Sacchi; Anna Nordlander; Caroline Berg Venemyr; Michaela Hanáková; Nicole García-Poutón; Ziad Emarah; Giovanni Paolo Maria Zambrotta; Raquel Nunes Rodrigues; Raul Cordoba; Gustavo-Adolfo Méndez; Monika M Biernat; Oliver A Cornely; Livio Pagano

doi:10.3390/cancers14225530

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Chiara Cattaneo
, Jon Salmanton-García^*
, Francesco Marchesi
, Shaimaa El-Ashwah
, Federico Itri
, Barbora Weinbergerová
, Maria Gomes Da Silva
, Michelina Dargenio
, Julio Dávila-Valls
, Sonia Martín-Pérez
, Francesca Farina
, Jaap Van Doesum
, Toni Valković
, Caroline Besson
, Christian Bjørn Poulsen
, Alberto López-García
, Pavel Žák
, Martin Schönlein
, Klára Piukovics
, Ozren Jaksic

Alba Cabirta, Natasha Ali, Uluhan Sili, Nicola Fracchiolla, Giulia Dragonetti, Tatjana Adžić-Vukičević, Monia Marchetti, Marina Machado, Andreas Glenthøj, Olimpia Finizio, Fatih Demirkan, Ola Blennow, Maria Chiara Tisi, Ali S Omrani, Milan Navrátil, Zdeněk Ráčil, Jan Novák, Gabriele Magliano, Moraima Jiménez, Carolina Garcia-Vidal, Nurettin Erben, Maria Ilaria Del Principe, Caterina Buquicchio, Rui Bergantim, Josip Batinić, Murtadha Al-Khabori, Luisa Verga, Tomáš Szotkowski, Michail Samarkos, Irati Ormazabal-Vélez, Stef Meers, Johan Maertens, László Imre Pinczés, Martin Hoenigl, Ľuboš Drgoňa, Annarosa Cuccaro, Yavuz M Bilgin, Avinash Aujayeb, Laman Rahimli, Stefanie Gräfe, Mariarita Sciumè, Miloš Mladenović, Gökçe Melis Çolak, Maria Vittoria Sacchi, Anna Nordlander, Caroline Berg Venemyr, Michaela Hanáková, Nicole García-Poutón, Ziad Emarah, Giovanni Paolo Maria Zambrotta, Raquel Nunes Rodrigues, Raul Cordoba, Gustavo-Adolfo Méndez, Monika M Biernat, Oliver A Cornely, Livio Pagano

^*Corresponding author for this work

Haematology

Research output: Contribution to journal › Article › Research › peer-review

Abstract

BACKGROUND: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines.

METHODS: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022.

RESULTS: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective.

CONCLUSIONS: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

Original language	English
Article number	5530
Journal	Cancers
Volume	14
Issue number	22
DOIs	https://doi.org/10.3390/cancers14225530
Publication status	Published - 10 Nov 2022

Access to Document

10.3390/cancers14225530Licence: CC BY

Cite this

Cattaneo, C., Salmanton-García, J., Marchesi, F., El-Ashwah, S., Itri, F., Weinbergerová, B., Gomes Da Silva, M., Dargenio, M., Dávila-Valls, J., Martín-Pérez, S., Farina, F., Van Doesum, J., Valković, T., Besson, C., Poulsen, C. B., López-García, A., Žák, P., Schönlein, M., Piukovics, K., ... Pagano, L. (2022). Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. Cancers, 14(22), Article 5530. https://doi.org/10.3390/cancers14225530

@article{3ae1475d293b4c669bbd0ad94af578e9,

title = "Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey",

abstract = "BACKGROUND: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines.METHODS: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022.RESULTS: Acute leukaemia and lymphoma were the most frequent HM (35.8\% and 35.1\%, respectively). Overall, 343 (76.2\%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6\%). An overall response rate was observed in 140 (40.8\%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3\%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1\%) than in those receiving treatment (27.4\%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2\%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective.CONCLUSIONS: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.",

author = "Chiara Cattaneo and Jon Salmanton-Garc{\'i}a and Francesco Marchesi and Shaimaa El-Ashwah and Federico Itri and Barbora Weinbergerov{\'a} and \{Gomes Da Silva\}, Maria and Michelina Dargenio and Julio D{\'a}vila-Valls and Sonia Mart{\'i}n-P{\'e}rez and Francesca Farina and \{Van Doesum\}, Jaap and Toni Valkovi{\'c} and Caroline Besson and Poulsen, \{Christian Bj{\o}rn\} and Alberto L{\'o}pez-Garc{\'i}a and Pavel {\v Z}{\'a}k and Martin Sch{\"o}nlein and Kl{\'a}ra Piukovics and Ozren Jaksic and Alba Cabirta and Natasha Ali and Uluhan Sili and Nicola Fracchiolla and Giulia Dragonetti and Tatjana Ad{\v z}i{\'c}-Vuki{\v c}evi{\'c} and Monia Marchetti and Marina Machado and Andreas Glenth{\o}j and Olimpia Finizio and Fatih Demirkan and Ola Blennow and Tisi, \{Maria Chiara\} and Omrani, \{Ali S\} and Milan Navr{\'a}til and Zden{\v e}k R{\'a}{\v c}il and Jan Nov{\'a}k and Gabriele Magliano and Moraima Jim{\'e}nez and Carolina Garcia-Vidal and Nurettin Erben and \{Del Principe\}, \{Maria Ilaria\} and Caterina Buquicchio and Rui Bergantim and Josip Batini{\'c} and Murtadha Al-Khabori and Luisa Verga and Tom{\'a}{\v s} Szotkowski and Michail Samarkos and Irati Ormazabal-V{\'e}lez and Stef Meers and Johan Maertens and Pincz{\'e}s, \{L{\'a}szl{\'o} Imre\} and Martin Hoenigl and {\v L}ubo{\v s} Drgo{\v n}a and Annarosa Cuccaro and Bilgin, \{Yavuz M\} and Avinash Aujayeb and Laman Rahimli and Stefanie Gr{\"a}fe and Mariarita Scium{\`e} and Milo{\v s} Mladenovi{\'c} and {\c C}olak, \{G{\"o}k{\c c}e Melis\} and Sacchi, \{Maria Vittoria\} and Anna Nordlander and \{Berg Venemyr\}, Caroline and Michaela Han{\'a}kov{\'a} and Nicole Garc{\'i}a-Pout{\'o}n and Ziad Emarah and Zambrotta, \{Giovanni Paolo Maria\} and \{Nunes Rodrigues\}, Raquel and Raul Cordoba and Gustavo-Adolfo M{\'e}ndez and Biernat, \{Monika M\} and Cornely, \{Oliver A\} and Livio Pagano",

year = "2022",

month = nov,

day = "10",

doi = "10.3390/cancers14225530",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

number = "22",

}

Cattaneo, C, Salmanton-García, J, Marchesi, F, El-Ashwah, S, Itri, F, Weinbergerová, B, Gomes Da Silva, M, Dargenio, M, Dávila-Valls, J, Martín-Pérez, S, Farina, F, Van Doesum, J, Valković, T, Besson, C, Poulsen, CB, López-García, A, Žák, P, Schönlein, M, Piukovics, K, Jaksic, O, Cabirta, A, Ali, N, Sili, U, Fracchiolla, N, Dragonetti, G, Adžić-Vukičević, T, Marchetti, M, Machado, M, Glenthøj, A, Finizio, O, Demirkan, F, Blennow, O, Tisi, MC, Omrani, AS, Navrátil, M, Ráčil, Z, Novák, J, Magliano, G, Jiménez, M, Garcia-Vidal, C, Erben, N, Del Principe, MI, Buquicchio, C, Bergantim, R, Batinić, J, Al-Khabori, M, Verga, L, Szotkowski, T, Samarkos, M, Ormazabal-Vélez, I, Meers, S, Maertens, J, Pinczés, LI, Hoenigl, M, Drgoňa, Ľ, Cuccaro, A, Bilgin, YM, Aujayeb, A, Rahimli, L, Gräfe, S, Sciumè, M, Mladenović, M, Çolak, GM, Sacchi, MV, Nordlander, A, Berg Venemyr, C, Hanáková, M, García-Poutón, N, Emarah, Z, Zambrotta, GPM, Nunes Rodrigues, R, Cordoba, R, Méndez, G-A, Biernat, MM, Cornely, OA & Pagano, L 2022, 'Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey', Cancers, vol. 14, no. 22, 5530. https://doi.org/10.3390/cancers14225530

TY - JOUR

T1 - Simultaneous Onset of Haematological Malignancy and COVID

T2 - An Epicovideha Survey

AU - Cattaneo, Chiara

AU - Salmanton-García, Jon

AU - Marchesi, Francesco

AU - El-Ashwah, Shaimaa

AU - Itri, Federico

AU - Weinbergerová, Barbora

AU - Gomes Da Silva, Maria

AU - Dargenio, Michelina

AU - Dávila-Valls, Julio

AU - Martín-Pérez, Sonia

AU - Farina, Francesca

AU - Van Doesum, Jaap

AU - Valković, Toni

AU - Besson, Caroline

AU - Poulsen, Christian Bjørn

AU - López-García, Alberto

AU - Žák, Pavel

AU - Schönlein, Martin

AU - Piukovics, Klára

AU - Jaksic, Ozren

AU - Cabirta, Alba

AU - Ali, Natasha

AU - Sili, Uluhan

AU - Fracchiolla, Nicola

AU - Dragonetti, Giulia

AU - Adžić-Vukičević, Tatjana

AU - Marchetti, Monia

AU - Machado, Marina

AU - Glenthøj, Andreas

AU - Finizio, Olimpia

AU - Demirkan, Fatih

AU - Blennow, Ola

AU - Tisi, Maria Chiara

AU - Omrani, Ali S

AU - Navrátil, Milan

AU - Ráčil, Zdeněk

AU - Novák, Jan

AU - Magliano, Gabriele

AU - Jiménez, Moraima

AU - Garcia-Vidal, Carolina

AU - Erben, Nurettin

AU - Del Principe, Maria Ilaria

AU - Buquicchio, Caterina

AU - Bergantim, Rui

AU - Batinić, Josip

AU - Al-Khabori, Murtadha

AU - Verga, Luisa

AU - Szotkowski, Tomáš

AU - Samarkos, Michail

AU - Ormazabal-Vélez, Irati

AU - Meers, Stef

AU - Maertens, Johan

AU - Pinczés, László Imre

AU - Hoenigl, Martin

AU - Drgoňa, Ľuboš

AU - Cuccaro, Annarosa

AU - Bilgin, Yavuz M

AU - Aujayeb, Avinash

AU - Rahimli, Laman

AU - Gräfe, Stefanie

AU - Sciumè, Mariarita

AU - Mladenović, Miloš

AU - Çolak, Gökçe Melis

AU - Sacchi, Maria Vittoria

AU - Nordlander, Anna

AU - Berg Venemyr, Caroline

AU - Hanáková, Michaela

AU - García-Poutón, Nicole

AU - Emarah, Ziad

AU - Zambrotta, Giovanni Paolo Maria

AU - Nunes Rodrigues, Raquel

AU - Cordoba, Raul

AU - Méndez, Gustavo-Adolfo

AU - Biernat, Monika M

AU - Cornely, Oliver A

AU - Pagano, Livio

PY - 2022/11/10

Y1 - 2022/11/10

N2 - BACKGROUND: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines.METHODS: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022.RESULTS: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective.CONCLUSIONS: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

AB - BACKGROUND: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines.METHODS: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022.RESULTS: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective.CONCLUSIONS: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

U2 - 10.3390/cancers14225530

DO - 10.3390/cancers14225530

M3 - Article

C2 - 36428621

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 22

M1 - 5530

ER -

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Abstract

Access to Document

Fingerprint

Cite this